Bliss GVS Pharma LimitedQ2 FY27 Results & Financial Update
Bliss GVS Pharma Limited: Q2 FY27 consolidated results and company financials – revenue ₹313.37 Cr, PAT ₹53.34 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Bliss GVS Pharma price & chart
Market price₹652.00
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Bliss GVS Pharma Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the quarter ended September 30, 2026 (Q2 FY27), Bliss GVS Pharma reported consolidated revenue from operations of INR 313.37 crore, representing a sequential increase of 9.73% compared to INR 285.58 crore recorded in Q1 FY27.
Total consolidated income for the quarter reached INR 321.67 crore, compared to INR 295.18 crore in the preceding quarter, driven by higher operational turnover and other income streams.
Profit before tax (PBT) for Q2 FY27 stood at INR 75.10 crore, remaining stable compared to INR 75.48 crore in Q1 FY27, reflecting balanced expense progression relative to revenue gains.
Profit after tax (PAT) for the quarter advanced to INR 53.34 crore, up 3.83% sequentially from INR 51.37 crore in the first quarter of fiscal 2027.
Basic and diluted earnings per share (EPS) for the quarter rose to INR 4.92, compared to INR 4.65 reported in the previous quarter.
Total tax expense for the period was recorded at INR 21.76 crore, moderating from INR 24.11 crore in Q1 FY27.
Finance costs for the quarter stood at INR 3.30 crore, while depreciation and amortisation expenses were reported at INR 10.50 crore.
01 · Business model
What does Bliss GVS Pharma do?
Bliss GVS Pharma Limited operates in the pharmaceutical and healthcare sector, engaging in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations.
The company maintains a significant global footprint, specializing in specialized therapeutic segments and anti-malarial products distributed across international markets alongside its domestic presence.
Manufacturing operations are anchored by facilities located in Palghar, Maharashtra, supported by a network of international subsidiaries and step-down entities spanning Africa, Europe, and Asia.
The corporate and registered headquarters are situated in Mumbai, India, directing consolidated operations across various manufacturing and marketing entities.
02 · Historical context
What shaped the business before this quarter
Previously, standalone financials included an impairment provision on investments in wholly owned subsidiary Bliss GVS International Pte. Ltd., Singapore, which has since been reversed following improved performance.
Pursuant to a Share Purchase Agreement dated May 23, 2026, and subsequent open offer, Anupam Rasayan India Limited, together with Mates Visa Consultancy Private Limited, acquired 50.07% of the paid-up equity share capital, becoming the holding and promoter company effective September 28, 2026.
During the half year ended September 30, 2026, the company allotted equity shares pursuant to the exercise of stock options under its ESOP Scheme, 2019.
03 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹313.37 Cr | ₹285.58 Cr |
| Total income | ₹321.67 Cr | ₹295.18 Cr |
| Profit before tax | ₹75.10 Cr | ₹75.48 Cr |
| Profit after tax | ₹53.34 Cr | ₹51.37 Cr |
| EPS | ₹4.92 | ₹4.65 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 17.0% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 24.0% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹8.30 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated revenue from operations expanded to INR 313.37 crore in Q2 FY27 from INR 285.58 crore in Q1 FY27, marking a sequential top-line expansion.
Other income contributed INR 8.30 crore to the consolidated total income of INR 321.67 crore during the quarter.
Interest income for the quarter was reported at INR 7.57 crore.
What drove margins
PAT margin on consolidated revenue stood at 17.02% for Q2 FY27, compared to 17.99% in Q1 FY27, reflecting a slight compression of approximately 97 basis points sequentially.
Tax outgo for the quarter decreased to INR 21.76 crore from INR 24.11 crore in the preceding quarter, providing support to net earnings.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The group's business activity falls within a single operating segment, viz 'Pharmaceutical and Healthcare', and no separate segment disclosures are applicable.
06 · Strategy & new businesses
How the company is trying to change its growth mix
Anupam Rasayan India Limited assumed control as the holding and promoter company effective September 28, 2026, holding 50.07% of the paid-up equity share capital.
07 · Reported developments
What changed operationally
Consolidated revenue from operations grew by 9.73% quarter-on-quarter to reach INR 313.37 crore.
Consolidated PAT increased by 3.83% sequentially to INR 53.34 crore for Q2 FY27.
08 · Items worth noticing
The line items that can distort a quick read
In standalone financial results, exceptional items for the quarter and half year ended September 30, 2026, include a reversal of impairment provision amounting to INR 4,108.61 lakh on investments in subsidiary Bliss GVS International Pte. Ltd. due to improved subsidiary performance and positive net worth.
09 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
For the half year ended September 30, 2026, net cash generated from operating activities on a consolidated basis stood at INR 4,500.92 lakh.
Net cash used in investing activities for the half year ended September 30, 2026, was INR 1,500.92 lakh.
Net cash used in financing activities for the half year ended September 30, 2026, was INR 1,880.19 lakh.
Capital allocation & funding
Consolidated finance costs for the quarter ended September 30, 2026, were reported at INR 3.30 crore.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Auditor review report
The statutory auditors issued an unmodified limited review report on the standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Reported update
Board meeting timings
The Board of Directors meeting commenced at 2:30 p.m. and concluded at 4:00 p.m. on October 29, 2026.
11 · Previous-quarter changes
What changed since the previous quarter
Revenue increased from INR 285.58 crore in Q1 FY27 to INR 313.37 crore in Q2 FY27.
PAT advanced from INR 51.37 crore in Q1 FY27 to INR 53.34 crore in Q2 FY27.
12 · Key Q&A
The quarter, answered directly
What does Bliss GVS Pharma do?
Bliss GVS Pharma Limited operates in the pharmaceutical and healthcare sector, engaging in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations.
What is the clearest takeaway from Q2 FY27?
For the quarter ended September 30, 2026 (Q2 FY27), Bliss GVS Pharma reported consolidated revenue from operations of INR 313.37 crore, representing a sequential increase of 9.73% compared to INR 285.58 crore recorded in Q1 FY27.
What drove revenue or demand?
Consolidated revenue from operations expanded to INR 313.37 crore in Q2 FY27 from INR 285.58 crore in Q1 FY27, marking a sequential top-line expansion.
What mattered most for margins or profitability?
PAT margin on consolidated revenue stood at 17.02% for Q2 FY27, compared to 17.99% in Q1 FY27, reflecting a slight compression of approximately 97 basis points sequentially.
What changed operationally beyond the headline numbers?
Anupam Rasayan India Limited assumed control as the holding and promoter company effective September 28, 2026, holding 50.07% of the paid-up equity share capital.
What should the next disclosure help confirm?
Monitor upcoming quarterly disclosures for revenue run-rate sustainability and margin trends under the new promoter ownership.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent financial performance: Monitor upcoming quarterly disclosures for revenue run-rate sustainability and margin trends under the new promoter ownership.
- 02
Integration and operational milestones: Track any strategic updates or operational synergies following the acquisition of control by Anupam Rasayan India Limited.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.